Johnson & Johnson’s stock rose 1.1% on Thursday, reaching $159.56. Trading volume dropped significantly, with 1.7 million ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

As of 20 February 2025, the index has steadily increased, rising 14.41% in the last 12 months and 4.21% year to date in 2025.

The final trades of the day with the Fast Money traders.

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital initiated coverage with a Buy rating on Johnson & Johnson (JNJ – ...

Empire Life Investments Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.6% in the 4th quarter, ...

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...